Program
etrasimod
Also written as “Etrasimod”, “APD334” and “Etrasimod Immediate Release (IR)”.
Its studies are mostly in Colitis, Ulcerative · Dermatitis, Atopic · Crohn Disease · Alopecia Areata · Eosinophilic Esophagitis, led by 2 companies.
Drug pageEtrasimod: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 203 open or running | phase 3since May 8, 2019 | May 13, 2015 | Jun 16, 2029phase 2 · NCT05287126 |
| Everstar Therapeutics | 11 open or running | phase 3since Nov 22, 2019 | Nov 22, 2019 | none ahead |
Also a collaborator on its studies: Arena is a wholly owned subsidiary of Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Everstar Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named etrasimodINNProposed as its International Nonproprietary Name in WHO's List 116 · before, APD334
- Nov 22, 2019First study: phase 3 study in Moderately to Severely Active Ulcerative ColitisFirst studyNCT04176588 · 341 enrolled · China
TargetBeta
“Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor Edg-8 modulator”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
Studies
The one study Everstar Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04176588Moderately to Severely Active Ulcerative Colitis · China | 3 | Active, not recruiting | Jul 2024 | 341 |
How it is read
Names in the registry
- “Etrasimod”, 19 entries
- “APD334”, 3 entries
- “etrasimod”, 1 entry
- “Etrasimod Immediate Release (IR)”, 1 entry
- “Etrasimod 1 mg”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 11 studies
- Dermatitis, Atopic, 2 studies
- Crohn Disease, 1 study
- Alopecia Areata, 1 study
- Eosinophilic Esophagitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.